Initiate broad clinical development program with RP2 and/or RP3
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Nov 2021
- Due
- 30 Jun 2022
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company remains on track to initiate a broad clinical development program with RP2 and/or RP3... around mid-year 2022.”
What we found
Evidence strength A What the grades mean
The company failed to initiate the broad clinical development program for RP2 and/or RP3 by the mid-year 2022 deadline, subsequently delaying the expected initiation to the first half of 2023.
-
A Replimune Group, Inc. 8-K filed 2022-08-04
“The Company remains on track to initiate its Phase 2 development program with RP2/3 in the first quarter of 2023.” ✓ confirmed on the page
-
A Replimune Group, Inc. 10-Q filed 2022-11-03
“We now expect to initiate this Phase 2 development work in the first half of 2023.” ✓ confirmed on the page
Market reaction: the shares moved -0.7% against the S&P 500 over the three sessions around the disclosure (3 Aug 2022 to 8 Aug 2022). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +365 days
- Language weakened: firm → expected
- 2 versions
-
Version 1 · original · stated 4 Nov 2021
Deadline 30 Jun 2022 (“mid-year 2022”) · wording firm
-
Version 2 · stated 18 May 2023
Deadline 30 Jun 2023 (“around mid-year 2023”) · wording expected
“The Company expects to initiate the Phase 2 program with RP2 and RP3 around mid-year.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Initiate
- Deliverable
- Broad clinical development program with RP2 and/or RP3
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-REPL-002645 · Corrections policy